Description: PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
Home Page: pilapharma.com
VAestergatan 1
Malmö,
211 21
Sweden
Phone:
46 7 39 03 69 69
Officers
| Name | Title |
|---|---|
| Ms. Dorte Xenia Gram | Founder, CEO & Director |
| Ms. Elna Lembrer Astrom | Chief Financial Officer |
| Mr. Miguel Lecumberri | Head of Compliance & Legal Affairs |
| Mr. Gustav Hanghoj Gram | Head of Office |
| Mr. Masoud Alavi | Head of Corp. Visual Communication |
| Mr. Andy Makin | Head of Toxicology |
| Ms. Maura McArdle | Head of BD & Quay Pharma |
| Mr. Mike Frodsham | CTO of Quay Pharma |
| Ms. Alison Foster | Head of Pre-Clinical - Quay Pharma |
| Mr. Simon Hamilton | Head of Global Bus. Devel. - Almac |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.0722 |
| Price-to-Sales TTM: | 25.2068 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |